New research by Alpharmaxim applies behavioural science to identify and understand prescribing choices in neurogenerative diseases - and highlights the need to optimise them

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

ALPHARMAXIM

More Like This

PR Newswire associated1

Groundbreaking pan-European study by Alpharmaxim and Aston University harnesses behavioural science to uncover factors influencing prescribing practice in Parkinson's Disease and identifies clear opportunities to improve treatment options

MULTI-MILLION POUND BOOST FOR RESEARCH PROJECTS AIMED AT DEVELOPING NEW TESTS, TREATMENTS AND DEVICES FOR NEURODEGENERATIVE DISEASES

PR Newswire associated0

QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson's Disease

Patient, Research and Industry Leaders Propose Biological Definition and First Biological Staging for Parkinson's Disease

PR Newswire associated0

AndzonBio2, the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise Announce a Collaboration to Develop First-in-Class Therapeutics for Neuroinflammation

Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Center for Brain Health Medicines Invite Proposals for 2024 ADDF-Harrington Scholar Award

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

PR Newswire associated0

FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE